Baidu
map

一图读懂:慢性肾病

2015-06-30 佚名 医学美图

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=30617, encodeId=810b3061efa, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30618, encodeId=f7fe30618ff, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30080, encodeId=9dc830080f1, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25b61624599, createdName=xykzfl, createdTime=Tue Jun 30 23:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30031, encodeId=09e5300311a, content=谁画的图,健康普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Jun 30 14:37:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=30617, encodeId=810b3061efa, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30618, encodeId=f7fe30618ff, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30080, encodeId=9dc830080f1, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25b61624599, createdName=xykzfl, createdTime=Tue Jun 30 23:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30031, encodeId=09e5300311a, content=谁画的图,健康普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Jun 30 14:37:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=30617, encodeId=810b3061efa, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30618, encodeId=f7fe30618ff, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30080, encodeId=9dc830080f1, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25b61624599, createdName=xykzfl, createdTime=Tue Jun 30 23:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30031, encodeId=09e5300311a, content=谁画的图,健康普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Jun 30 14:37:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-06-30 xykzfl

    收藏

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=30617, encodeId=810b3061efa, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30618, encodeId=f7fe30618ff, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:35:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30080, encodeId=9dc830080f1, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25b61624599, createdName=xykzfl, createdTime=Tue Jun 30 23:39:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30031, encodeId=09e5300311a, content=谁画的图,健康普及, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Jun 30 14:37:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-06-30 owlhealth

    谁画的图,健康普及

    0

相关资讯

J Am Soc Nephro:慢性肾病可能增加妊娠风险

在妊娠期间患有轻度肾病疾病可能增加不良妊娠结局的风险。我们评估了与慢性肾病相关的不良妊娠结局的风险。在被称为都灵-卡利亚里观察性研究(TOCOS)的研究中,我们将504名患有慢性肾脏疾病的孕妇与836名没有慢性肾脏疾病孕妇的妊娠结局进行比较。 高血压、蛋白尿(> 1 g / d),系统性疾病,慢性肾病阶段作为基线评估。本研究中,在第一阶段慢性肾脏疾病,早产与基线高血压(OR,3.42;95

BMC Oral Health:发展中国家慢性肾病患者的口腔病损管理

BMC Oral Health:慢性肾病与口腔病损对控制全身性疾病包括慢性肾病(CKD)的患者,口腔健康保健的重要性已广为人知。很多CKD患者都有相关的口腔表现,然而,大众对口腔健康保健的重视仍然不足,尤其是在肾脏疾病所造成的医疗负担较大的发展中国家。研究纳入并检查了90例健康对照组,90例CKD患者,共180例研究对象。基于WHO指导的口腔黏膜病的诊断和流行病学评估口腔黏膜。确定尿常规、血肌酐水

NEJM:慢性肾病,让她失去了美丽的指甲

一名59岁的女士于16年前因左肾患有多囊肾脏疾病做了肾脏移植手术,自3年前起开始发现自己的指甲发生了改变。在此之前,她一直接受强的松、霉酚酸酯和他莫克斯的免疫抑制治疗。 该女士现正处于肾脏疾病的4期,在过去的一年中,她的血肌酐水平(1.7-2.2mg/dl「150-194umol/l」)和血尿素氮(26-28mg/dl「9.3-13.6mmol/l」)均出现了升高的现象。

PLOS MED:HIV感染者患慢性肾病的风险评分模型建立

HIV感染现在已经成为了一种慢性可控的感染,感染者的预期寿命可以接近普通人。尽管联合抗逆转录病毒治疗已经使结果得到改善,但HIV阳性患者仍遭受着逐渐升高的发病率,其中就包括慢性肾病。据报道,HIV感染者中患有慢性肾病者高达33%。发展和实施慢性肾病风险评分可以使得增加具有潜在肾脏毒性的抗逆转录病毒治疗方案的风险和好处形成对比,并且确定慢性肾病的最大风险。研究人员正是要建立一种简单、经过外部验证的可

Am J Kidney Dis:慢性肾病患者使用华法林会增加出血风险吗?

2015年5月,发表于《Am J Kidney Dis》的一篇文章介绍了一项考察慢性肾疾病患者eGFR-INR相互作用对于出血风险影响的研究。结果显示,INR≥4时,eGFR较低的患者出血风险差异较高。此外,由于INR逆转速度较慢,所以出血风险有所延长。背景:慢性肾疾病患者中,抗凝管理非常困难,频繁的超过治疗范围的国际标准化比率(INR≥4)增加出血风险。因此,我们旨在评估,INR和较低的估计肾小

Ardelyx重磅药物tenapanor(NHE3受体抑制剂)二期临床试验失利

生物医药公司的重心永远是药物,一个成功的药物能够帮助公司瞬间“登上人生巅峰”,而一旦失败,则会导致投资人避如蛇蝎。最近,Ardelyx医药公司就遭遇了这种痛苦。周二被迫宣布公司开发的重磅药物tenapanor在治疗三期慢性肾病和二型糖尿病的临床二期研究中遭遇滑铁卢,消息一出,投资者信心大减直接导致公司股票暴跌。 在这项有154名患者参与的临床二期研究中,tenapanor未能达到预期终点——

Baidu
map
Baidu
map
Baidu
map